As filed with the Securities and Exchange Commission on March 17, 2022
Registration No. 333-
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM S-8
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933
Cytek Biosciences, Inc.
(Exact name of registrant as specified in its charter)
| Delaware | 47-2547526 | |
(State or other jurisdiction of incorporation or organization) | (I.R.S. Employer Identification No.) |
47215 Lakeview Boulevard
Fremont, California 94538
(877) 922-9835
(Address of Principal Executive Offices) (Zip Code)
Cytek Biosciences, Inc. 2021 Equity Incentive Plan
Cytek Biosciences, Inc. 2021 Employee Stock Purchase Plan
(Full title of the plans)
Wenbin Jiang, Ph.D.
President and Chief Executive Officer
Cytek Biosciences, Inc.
47215 Lakeview Boulevard
Fremont, California 94538
(877) 922-9835
(Name, address, including zip code, and telephone number, including area code, of agent for service)
Please send copies of all communications to:
Gordon K. Ho Cooley LLP 3175 Hanover Street Palo Alto, California 94304 (650) 843-5000 (206) 452-8753 | Valerie Barnett General Counsel Cytek Biosciences, Inc. 47215 Lakeview Boulevard Fremont, California 94538 (877) 922-9835 |
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer | ☐ | Accelerated filer | ☐ | |||
Non-accelerated filer | ☒ | Smaller reporting company | ☒ | |||
Emerging growth company | ☒ |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐
REGISTRATION OF ADDITIONAL SHARES
PURSUANT TO GENERAL INSTRUCTION E
Pursuant to General Instruction E of Form S-8, the Registrant is filing this Registration Statement with the Securities and Exchange Commission (the “Commission”) to register 5,349,986 additional shares of common stock under the Registrant’s 2021 Equity Incentive Plan and 1,337,496 additional shares of common stock under the Registrant’s 2021 Employee Stock Purchase Plan pursuant to the provisions of those plans providing for an automatic increase in the number of shares reserved for issuance under such plans. This Registration Statement hereby incorporates by reference the contents of the Registrant’s registration statement on Form S-8 filed with the Commission on July 23, 2021 (Registration No. 333-258153).
PART II
| ITEM 3. | INCORPORATION OF DOCUMENTS BY REFERENCE |
The following documents filed by Registrant with the Commission are incorporated by reference into this Registration Statement:
(a) The Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021, filed with the Commission on March 17, 2022;
(b) The Registrant’s Current Reports on Form 8-K filed with the Commission on January 6, 2022 and March 2, 2022; and
(c) The description of the Registrant’s Common Stock contained in the registration statement on Form 8-A registering the Registrant’s Common Stock under Section 12 of the Exchange Act filed with the Commission on July 19, 2021, including any amendments or reports filed for purposes of updating such description.
All other reports and documents subsequently filed by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act (other than Current Reports furnished under Item 2.02 or Item 7.01 of Form 8-K and exhibits furnished on such form that relate to such items) on or after the date of this Registration Statement and prior to the filing of a post-effective amendment to this Registration Statement which indicates that all securities offered have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference herein and to be a part of this Registration Statement from the date of the filing of such reports and documents. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any subsequently filed document that also is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.
| Item 8. | Exhibits. |
The following exhibits are filed herewith:
| Incorporated by Reference | ||||||||||||
Exhibit Number | Exhibit Description | Form | File No. | Exhibit | Filing Date | Filed Herewith | ||||||
| 4.1 | Amended and Restated Certificate of Incorporation of Cytek Biosciences, Inc. | 8-K | 001-40632 | 3.1 | 7/27/2021 | |||||||
II-1
II-2
Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Fremont, State of California, on March 17, 2022.
| CYTEK BIOSCIENCES, INC. |
/s/ Wenbin Jiang, Ph.D. |
| Wenbin Jiang, Ph.D. |
| President, Chief Executive Officer and Director |
KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Wenbin Jiang, Patrik Jeanmonod and Valerie Barnett, and each of them, as his or her true and lawful attorney-in-fact and agent with the full power of substitution, for him or her, in any and all capacities, to sign any and all amendments to this Registration Statement (including post-effective amendments to this Registration Statement on Form S-8), and to file the same, with all exhibits thereto and other documents in connection therewith, with the Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully for all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or his or her substitutes, may lawfully do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Act, this Registration Statement has been signed by the following persons on behalf of the Registrant in the capacities and on the dates indicated:
Name | Title | Date | ||
/s/ Wenbin Jiang, Ph.D. |
President, Chief Executive Officer and Director (Principal Executive Officer) |
March 17, 2022 | ||
| Wenbin Jiang, Ph.D. | ||||
/s/ Patrik Jeanmonod | Chief Financial Officer (Principal Financial and Accounting Officer) | March 17, 2022 | ||
| Patrik Jeanmonod | ||||
/s/ Ming Yan, Ph.D. | Chief Technology Officer and Director | March 17, 2022 | ||
| Ming Yan, Ph.D. | ||||
/s/ Jack Ball | Director | March 17, 2022 | ||
| Jack Ball | ||||
/s/ Tess Cameron | Director | March 17, 2022 | ||
| Tess Cameron | ||||
/s/ Feng Deng | Director | March 17, 2022 | ||
| Feng Deng | ||||
/s/ Gisele Dion | Director | March 17, 2022 | ||
| Gisele Dion | ||||
/s/ Vera Imper, Ph.D. | Director | March 17, 2022 | ||
| Vera Imper, Ph.D. | ||||
II-3
